Modulation of MiR-145-5p and MiR-146b-5p Levels is Linked to Reduced Parasite Load in H9C2 Trypanosoma Cruzi Infected Cardiomyoblasts
Authors
Affiliations
In the heart tissue of acutely Trypanosoma cruzi-infected mice miR-145-5p and miR-146b-5p are, respectively, downregulated and upregulated. Here, we used the H9C2 rat cardiomyoblast cell line infected with the Colombian T. cruzi strain to investigate the parasite-host cell interplay, focusing on the regulation of miR-145-5p and miR-146b-5p expression. Next, we explored the effects of interventions with the trypanosomicidal drug Benznidazole (Bz) alone or combined with Pentoxifylline (PTX), a methylxanthine derivative shown to modulate immunological and cardiac abnormalities in a model of chronic chagasic cardiomyopathy, on parasite load and expression of miR-145-5p and miR-146b-5p. The infection of H9C2 cells with trypomastigote forms allowed parasite cycle with intracellular forms multiplication and trypomastigote release. After 48 and 144 h of infection, upregulation of miR-145-5p (24 h: 2.38 ± 0.26; 48 h: 3.15 ± 0.9-fold change) and miR-146b-5b (24 h: 2.60 ± 0.46; 48 h: 2.97 ± 0.23-fold change) was detected. The peak of both miRNA levels paralleled with release of trypomastigote forms. Addition of 3 µM and 10 µM of Bz 48 h after infection reduced parasite load but did not interfere with miR-145-5p and miR-146b-5p levels. Addition of PTX did not interfere with Bz-induced parasite control efficacy. Conversely, combined Bz + PTX treatment decreased the levels of both microRNAs, resembling the expression levels detected in non-infected H9C2 cells. Moreover, the use of miR-145-5p and miR-146b-5p mimic/inhibitor systems before infection of H9C2 cells decreased parasite load, 72 h postinfection. When H9C2 cells were treated with miR-145-5p and miR-146b-5p mimic/inhibitor 48 h after infection, all the used systems, except the miR-146b-5p inhibitor, reduced parasite load. Altogether, our data indicate that these microRNAs putatively control signaling pathways crucial for parasite-host cell interaction. Thus, miR-145-5p and miR-146b-5p deserve to be further investigated as biomarkers of parasite control and tools to identify therapeutic adjuvants to etiological treatment in Chagas disease.
Dr. Jekyll or Mr. Hyde: The multifaceted roles of miR-145-5p in human health and disease.
Rahman M, Ghorai S, Panda K, Santiago M, Aggarwal S, Wang T Noncoding RNA Res. 2024; 11:22-37.
PMID: 39736851 PMC: 11683234. DOI: 10.1016/j.ncrna.2024.11.001.
Recent advances in the development and clinical application of miRNAs in infectious diseases.
Nunes S, Bastos R, Marinho A, Vieira R, Benicio I, de Noronha M Noncoding RNA Res. 2024; 10:41-54.
PMID: 39296638 PMC: 11406675. DOI: 10.1016/j.ncrna.2024.09.005.
Benznidazole-Loaded Polymeric Nanoparticles for Oral Chemotherapeutic Treatment of Chagas Disease.
Sousa L, Duarte T, Xavier V, das Merces A, Vieira G, Martins M Pharmaceutics. 2024; 16(6).
PMID: 38931921 PMC: 11207087. DOI: 10.3390/pharmaceutics16060800.
Ribeiro H, Galdino O, Costa de Souza K, Rosa Neta A, Lin-Wang H, Cunha-Neto E PLoS Negl Trop Dis. 2024; 18(2):e0011865.
PMID: 38300899 PMC: 10833550. DOI: 10.1371/journal.pntd.0011865.
Villar S, Herreros-Cabello A, Callejas-Hernandez F, Maza M, Del Moral-Salmoral J, Gomez-Montes M Sci Rep. 2024; 14(1):1187.
PMID: 38216639 PMC: 10786931. DOI: 10.1038/s41598-024-51487-9.